Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Stretch Mark Cream

ARYx Therapeutics Inc. Updates Progress With Tecarfarin EmbraceAC Study
ARYx Therapeutics Inc. (NASDAQ:ARYX), a biopharmaceutical company, announced today that the database for the EmbraceAC study has been locked and the study remains on schedule, with the efficacy and safety results to be available during the week of July 6, 2009. The study was designed to compare its oral anticoagulation therapy, tecarfarin (previously ATI-5923), against the leading anticoagulant agent, warfarin. The purpose of the trial is to evaluate whether tecarfarin is superior to warfarin in its ability to maintain patients within a target therapeutic range of the level of anticoagulation as measured by INR (International Normalized Ratio). Based upon recent interactions with the U. S. Food and Drug Administration (FDA), ARYx believes this trial could be positioned as one of the required registration studies for tecarfarin.
generic viagra online
Investigation Finds Problem Nurses Stay On Job Amid Nursing Shortage
Propublica/The Los Angeles Times found that "the board charged with overseeing California"s 350,000 registered nurses often takes years to act on complaints of egregious misconduct, leaving nurses accused of wrongdoing free to practice without restrictions ... It"s a high-stakes gamble that no one will be hurt as nurses with histories of drug abuse, negligence, violence and incompetence continue to provide care across the state. While the inquiries drag on, many nurses maintain spotless records. New employers and patients have no way of knowing the risks." Drugshop to buy zoloft online and other pills.
News of the day
Weight Loss In Old Age May Signal Dementia
A new study shows that older people who are thinner or are losing weight quickly are at a higher risk of developing dementia, especially if they started out overweight or obese. The research is published in the May 19, 2009, print issue of Neurology®, the medical journal of the American Academy of Neurology.
Diagnostics

Fluxion Biosciences Awarded NCI Grant For Development Of Rare Cell Isolation Platform

Fluxion Biosciences, a leading developer of microfluidic systems for cellular analysis in life science research, announced that it has received a $200K grant from the National Cancer Institute (NCI) for the development of a rare cell isolation platform for diagnostic and research applications. The Phase One Small Business Innovation Research Grant will enable Fluxion to further develop its innovative microfluidic platform. The endpoints of this research include enhanced methods for detecting circulating tumor cells that appear in very low concentrations in the early stages of cancer. Circulating tumor cells (CTCs) are cells that detach from a primary tumor and circulate throughout the bloodstream. These cells are part of the metastasizing process that leads to the progression of the disease. It is widely believed that the detection of CTCs in the blood is an important factor in monitoring an individual"s baseline condition and ongoing response to therapy. Despite the high value of this information, these tests are rarely performed due to the difficulty in tracking CTCs, which can appear in as little as one in one billion blood cells. This newly awarded grant is focused on the development of a microfluidic system that enhances the detection ability of CTCs as well as other rare cell types. The principal aims of this grant include the design of novel microfluidic systems for magnetic-bead based cell separations and the associated control instrumentation. "We are excited to receive this NCI grant for this compelling application of our microfluidic technology," said Carolyn Conant, Ph.D., project leader for the grant. "The ability to detect and isolate rare cells can have a profound impact in the fields of oncology, immunology and neonatal care." Fluxion Biosciences


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009